The Case for Less, Not More, US FDA Regulation John A. VernonJoseph H. Golec Editorial 23 September 2012 Pages: 637 - 640
Challenges in Health State Valuation in Paediatric Economic Evaluation Wendy J. Ungar Current Opinion 23 September 2012 Pages: 641 - 652
Cost-of-Illness Studies Allison LargJohn R. Moss Practical Application 23 September 2012 Pages: 653 - 671
Using QALYs in Cancer Martina GarauKoonal K. ShahMichael F. Drummond Review Article 23 September 2012 Pages: 673 - 685
US FDA Modernization Act, Section 114 Peter J. NeumannPei-Jung LinTom E. Hughes Short Communication 23 September 2012 Pages: 687 - 692
Cost Estimation of Cardiovascular Disease Events in the US Amy K. O’SullivanJaime RubinDavid Thompson Original research Article 23 September 2012 Pages: 693 - 704
Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis Annette C. ReboliColeman RotsteinMiriam Tarallo Original Research Article 23 September 2012 Pages: 705 - 717
Estimating the Relationship between Preference-Based Generic Utility Instruments and Disease-Specific Quality-of-Life Measures in Severe Chronic Constipation Mark ParkerAlan HaycoxJane Graves Original Research Article 23 September 2012 Pages: 719 - 730